Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3048% below fair value
$2.96−0.17 (-5.43%)
Close on Nov 12, 2026Market cap $238.49MP/E 11.8Yield –
Protalix BioTherapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Protalix BioTherapeutics's gross margin for the twelve months ending Sep 30, 2026 was 71.2%. For fiscal 2025 it was 48.8%, against 54.5% the year before. The highest annual figure on record is 103.3% in fiscal 2010.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.8% | −5.6 |
| FY2024 | Dec 31, 2024 | 54.5% | −10.5 |
| FY2023 | Dec 31, 2023 | 64.9% | +6.0 |
| FY2022 | Dec 31, 2022 | 58.9% | +1.5 |
| FY2021 | Dec 31, 2021 | 57.4% | −25.3 |
| FY2020 | Dec 31, 2020 | 82.7% | +2.6 |
| FY2019 | Dec 31, 2019 | 80.1% | +7.2 |
| FY2018 | Dec 31, 2018 | 72.8% | +53.8 |
| FY2017 | Dec 31, 2017 | 19.0% | +10.3 |
| FY2016 | Dec 31, 2016 | 8.7% | −74.6 |
| FY2015 | Dec 31, 2015 | 83.3% | +1.2 |
| FY2014 | Dec 31, 2014 | 82.1% | +6.8 |
| FY2012 | Dec 31, 2012 | 75.4% | +58.2 |
| FY2011 | Dec 31, 2011 | 17.2% | −86.1 |
| FY2010 | Dec 31, 2010 | 103.3% | +924.7 |
| FY2009 | Dec 31, 2009 | -821.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 64.1% | +10.7 |
| Q2 FY2026 | Jun 30, 2026 | 61.0% | −1.5 |
| Q1 FY2026 | Mar 31, 2026 | 87.8% | +68.7 |
| Q4 FY2025 | Dec 31, 2025 | 49.4% | −29.3 |
| Q3 FY2025 | Sep 30, 2025 | 53.4% | +0.0 |
| Q2 FY2025 | Jun 30, 2025 | 62.5% | +32.7 |
| Q1 FY2025 | Mar 31, 2025 | 19.1% | −11.5 |
| Q4 FY2024 | Dec 31, 2024 | 78.7% | +63.1 |
| Q3 FY2024 | Sep 30, 2024 | 53.4% | +0.7 |
| Q2 FY2024 | Jun 30, 2024 | 29.8% | −52.7 |
| Q1 FY2024 | Mar 31, 2024 | 30.6% | −37.2 |
| Q4 FY2023 | Dec 31, 2023 | 15.5% | −56.6 |
| Q3 FY2023 | Sep 30, 2023 | 52.7% | +2.6 |
| Q2 FY2023 | Jun 30, 2023 | 82.5% | +29.2 |
| Q1 FY2023 | Mar 31, 2023 | 67.8% | +5.3 |
| Q4 FY2022 | Dec 31, 2022 | 72.2% | +9.0 |
| Q3 FY2022 | Sep 30, 2022 | 50.1% | −19.2 |
| Q2 FY2022 | Jun 30, 2022 | 53.3% | +26.9 |
| Q1 FY2022 | Mar 31, 2022 | 62.5% | +4.6 |
| Q4 FY2021 | Dec 31, 2021 | 63.2% | −22.7 |
| Q3 FY2021 | Sep 30, 2021 | 69.3% | −14.9 |
| Q2 FY2021 | Jun 30, 2021 | 26.4% | −57.0 |
| Q1 FY2021 | Mar 31, 2021 | 57.9% | −19.6 |
| Q4 FY2020 | Dec 31, 2020 | 85.9% | +7.9 |
| Q1 FY2020 | Mar 31, 2020 | 84.2% | +3.8 |
| Q4 FY2019 | Dec 31, 2019 | 83.4% | −8.2 |
| Q3 FY2019 | Sep 30, 2019 | 77.5% | +266.6 |
| Q2 FY2019 | Jun 30, 2019 | 78.0% | +86.8 |
| Q1 FY2019 | Mar 31, 2019 | 80.4% | +44.6 |
| Q4 FY2018 | Dec 31, 2018 | 91.6% | +70.3 |
| Q3 FY2018 | Sep 30, 2018 | -189.1% | −208.5 |
| Q2 FY2018 | Jun 30, 2018 | -8.8% | −22.0 |
| Q1 FY2018 | Mar 31, 2018 | 35.8% | +8.1 |
| Q4 FY2017 | Dec 31, 2017 | 21.3% | +15.1 |
| Q3 FY2017 | Sep 30, 2017 | 19.4% | +10.4 |
| Q2 FY2017 | Jun 30, 2017 | 13.1% | – |
| Q1 FY2017 | Mar 31, 2017 | 27.7% | – |
| Q4 FY2016 | Dec 31, 2016 | 6.2% | – |
| Q3 FY2016 | Sep 30, 2016 | 9.0% | – |
See a number that looks wrong?